-
1
-
-
79961107025
-
-
online]. Available from URL: Accessed 2012 May 31]
-
Biologics Price Competition and Innovation Act (2009) [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceCompliance Regulatory Information/UCM216146.pdf [Accessed 2012 May 31]
-
(2009)
Biologics Price Competition.Innovation Act
-
-
-
2
-
-
84876082884
-
-
355(b)(2) and 355(j)) [online]. Available from URL [Accessed 2012 May 31]
-
See section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355(b)(2) and 355(j)) [online]. Available from URL: http://www.fda.gov [Accessed 2012 May 31]
-
See Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C
-
-
-
3
-
-
33644952525
-
-
Committee For Medicinal Products For Human Use (CHMP. CHMP43704 [online]. Available From URL: [Accessed 2012 April 27
-
Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. CHMP/437/04 [online]. Available from URL: http://www.emea.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003517.pdf [Accessed 2012 April 27]
-
Guideline On Similar Biological Medicinal Products
-
-
-
4
-
-
67549097000
-
Regulatory aspects of biosimilars in Europe
-
Zuniga L, Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol 2009; 27: 385-7
-
(2009)
Trends Biotechnol
, vol.27
, pp. 385-387
-
-
Zuniga, L.1
Calvo, B.2
-
7
-
-
84876095755
-
-
Committee For Medicinal Products For Human Use (CHMP. EMACHMPBMWP5726432011[online]. Available From URL: [Accessed 2012 May 31]
-
Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the guideline on similar biological medicinal product. EMA/CHMP/BMWP/572643/2011[online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2011/11/ WC500117987.pdf [Accessed 2012 May 31]
-
Concept Paper On The Revision Of The Guideline On Similar Biological Medicinal Product
-
-
-
10
-
-
84876081314
-
-
Committee For Medicinal Products For Human Use (CHMP. EMEACHMPBMWP102046 [online]. Available from URL: [Accessed 2012 May 31]
-
Committee for Medicinal Products for Human Use (CHMP). Non-clinical and clinical development of similar medicinal products containing recombinant interferon alpha. EMEA/CHMP/BMWP/102046/2006 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Sci entific-guideline/2009/ 09/WC500003930.pdf [Accessed 2012 May 31]
-
(2006)
Non-Clinical And Clinical Development Of Similar Medicinal Products Containing Recombinant Interferon Alpha
-
-
-
11
-
-
84876089219
-
-
Committee For Medicinal Products For Human Use (CHMP. EMEA CHMPBMWP30163608 [online]. Available From URL:[Accessed 2012 May 31]
-
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing recombinant erythropoietins. EMEA/ CHMP/BMWP/301636/08 [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/04/ WC500089474.pdf [Accessed 2012 May 31]
-
Similar Biological Medicinal Products Containing Recombinant Erythropoietins
-
-
-
14
-
-
84871481289
-
-
Committee For Medicinal Products For Human Use (CHMP. EMACHMPBMWP4035432010 [online]. Available From URL: [Accessed 2012 May 31]
-
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing monoclonal antibodies: Non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2012/06/WC500128686.pdf [Accessed 2012 May 31]
-
Similar Biological Medicinal Products Containing Monoclonal Antibodies: Non-clinical And Clinical Issues
-
-
-
15
-
-
84876070851
-
-
Committee For Medicinal Products For Human Use (CHMP. CHMPBMWP6712922010 [online]. Available From URL: [Accessed 2012 May 31]
-
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing recombinant follicle stimulation hormone. CHMP/BMWP/671292/2010 [online]. Available from URL: http:// www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2011/ 11/WC500117986.pdf [Accessed 2012 May 31]
-
Similar Biological Medicinal Products Containing Recombinant Follicle Stimulation Hormone
-
-
-
16
-
-
84876089219
-
-
Committee For Medicinal Products For Human Use (CHMP. CHMPBMWP 6520002010 [online]. Available From URL: [Accessed 2012 May 31]
-
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal product containing interferon beta. CHMP/BMWP/ 652000/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/ en-GB/document-library/ Scientific-guideline/2012/01/WC500120652.pdf [Accessed 2012 May 31]
-
Similar Biological Medicinal Product Containing Interferon Beta
-
-
-
17
-
-
84876084861
-
-
Guidance For Industry: Scientific Considerations In Demonstrating Biosimilarity To A Reference Product February 2012 [online].Available FromURL:[Accessed 2012May 31]
-
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product, February 2012 [online].Available fromURL: http://www.fda.gov/Drugs/DevelopmentApproval Process/HowDrugsareDevelopedandApproved/ApprovalApplications/Therapeu ticBiologicApplications/Biosimilars/default.htm [Accessed 2012May 31]
-
Center For Drug Evaluation And Research (CDER) Center For Biologics Evaluation And Research (CBER
-
-
-
18
-
-
84876084861
-
-
Guidance For Industry: Quality Considerations In Demonstrating Biosimilarity To A Reference Protein Product February 2012 [online]. Available From URL: [Accessed 2012 May 31]
-
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product, February 2012 [online]. Available from URL:http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval Applications/TherapeuticBiologicApplications/Biosimilars/default.htm [Accessed 2012 May 31]
-
Center For Drug Evaluation And Research (CDER) Center For Biologics Evaluation And Research (CBER
-
-
-
19
-
-
84874151018
-
-
[online]. Available from URL Questions And Answers Regarding Implementation Of The Biologics Price Competition And Innovation Act Of [Accessed 2012 May 31]
-
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009 [online]. Available from URL: http://www.fda.gov/Drugs/Development ApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplica tions/ TherapeuticBiologicApplications/Biosimilars/default.htm [Accessed 2012 May 31]
-
(2009)
Center For Drug Evaluation And Research (CDER) Center For Biologics Evaluation And Research (CBER
-
-
-
20
-
-
34548841437
-
Biotechs go generic: The same but different
-
DOI 10.1038/449274a, PII 449274A
-
Ledford H. Biotechs go generic: The same but different. Nature 2007; 449: 274-6 (Pubitemid 47443456)
-
(2007)
Nature
, vol.449
, Issue.7160
, pp. 274-276
-
-
Ledford, H.1
-
21
-
-
84876086466
-
-
online]. Available from URL: [Accessed 2012 May 31]
-
Gatyas G. Gobal biologics spending (2010) [online]. Available from URL: https://www.brainshark.com/imshealth/vu?pi=zGBzFL1RkzyjTz00 [Accessed 2012 May 31]
-
(2010)
Gobal Biologics Spending
-
-
Gatyas, G.1
-
22
-
-
77955636779
-
Biosimilars: Pharmacovigilance and risk management
-
Zuniga L, Calvo B. Biosimilars: Pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010; 19: 661-9
-
(2010)
Pharmacoepidemiol Drug Saf
, vol.19
, pp. 661-669
-
-
Zuniga, L.1
Calvo, B.2
-
23
-
-
79961116944
-
Developing the nation's biosimilars program
-
Kozlowski S, Woodcock J, Midthun K, et al. Developing the nation's biosimilars program. N Engl J Med 2011; 365: 385-8
-
(2011)
N Engl J Med
, vol.365
, pp. 385-388
-
-
Kozlowski, S.1
Woodcock, J.2
Midthun, K.3
|